USSTOCK.TODAY
Market Closed
Log in Sign up

Zebra Therapeutics Awaits September Quarter Results Amid US Revenue Growth and European Uncertainty

Earnings Whispers · ·by G4L

ZVRA
ZVRA Zevra Therapeutics Inc
$12.14 +4.75%
View chart & analysis →
  1. 1Zebra Therapeutics is projected to report September quarter revenue of $36.7 million, according to Wall Street estimates.
  2. 2US MyPlyfa net revenue recorded $30.2 million, a 23% increase from the previous quarter.
  3. 3Zebra Therapeutics maintains a debt-free balance sheet with $260.2 million in cash.

So what's the key point?

Zebra Therapeutics' September quarter revenue is expected to meet analyst expectations. The company is in a solid position with growing US revenue and no debt.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Zevra Therapeutics Beats Q3 Estimates and Sets New MIPLYFFA Sales Record Earnings Whispers · 4d agoUnited Therapeutics Posts Q2 Net Income of $333 Million Associated Press +1 · Aug 5Comparison of Diesel Reduction Strategies: Range Energy Releases White Paper FreightWaves · Oct 27
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news